DermatologyResearch Phase

Biopeptide CL (Palmitoyl Tripeptide-5)

Topical

Overview

Palmitoyl Tripeptide-5 is a synthetic lipopeptide consisting of a tripeptide sequence conjugated to palmitic acid to enhance dermal penetration. The peptide is designed to stimulate collagen synthesis by mimicking the activity of thrombospondin-1, a matricellular protein involved in extracellular matrix remodeling.

Mechanism of Action

Its therapeutic rationale centers on attenuating photoaging and improving skin elasticity through upregulation of Types I and III collagen in dermal fibroblasts..

Research Summary & Key Findings

In vitro studies have demonstrated increased collagen gene expression and decreased matrix metalloproteinase activity in cultured human fibroblasts. Small-scale human pilot studies reported improvements in skin roughness and fine lines after 12 weeks of topical application, though peer-reviewed controlled trial data remain limited.

Clinical Status

Research Phase

Biopeptide CL (Palmitoyl Tripeptide-5) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Biopeptide CL (Palmitoyl Tripeptide-5) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Biopeptide CL (Palmitoyl Tripeptide-5).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.